https://www.selleckchem.com/pr....oducts/GSK461364.htm
We aimed to examine the safety and efficacy of bevacizumab and carboplatin in patients with breast cancer brain metastases. We enrolled patients with breast cancer and 1 measurable new or progressive brain metastasis. Patients received bevacizumab 15 mg/kg intravenously (IV) on cycle 1 day 1 and carboplatin IV AUC = 5 on cycle 1 day 8. Patients with HER2-positive disease also received trastuzumab. In subsequent cycles, all drugs were administered on day 1 of each cycle. Contrast-enhanced brain MRI was performed at baseline, 24-96
Like
Comment
Share
